Is BPC-157 Legal in Washington State?

The Short Answer on BPC-157 and Washington State

BPC-157 is not legal to prescribe, dispense, or compound for human use in Washington State through standard medical channels. The FDA's May 2023 decision to place BPC-157 on the Category 2 bulk drug substances list ended its pathway through 503A and 503B compounding pharmacies for human administration. Washington State's Uniform Controlled Substances Act and the Washington State Pharmacy Quality Assurance Commission (PQAC) do not add any independent exceptions.

That is the blunt answer. The sections below explain the federal framework, what the FDA's bulk substances list actually means, how Washington's pharmacy board interprets compounding restrictions, and what legitimate options remain for patients and researchers.

What Is BPC-157 and Why Does Its Legal Status Matter?

The Peptide Itself

BPC-157, short for Body Protection Compound-157, is a synthetic pentadecapeptide derived from a sequence found in human gastric juice. It consists of 15 amino acids. Animal studies published in peer-reviewed literature suggest it may reduce inflammation and support tissue repair across connective tissue, muscle, and the gut, but no randomized controlled trial in humans has established safety or efficacy for any indication. [1]

Why the Legal Question Is Complicated

Because BPC-157 is a peptide rather than a small-molecule drug, some suppliers market it as a "research chemical" or "not for human consumption" product. That labeling does not make it legal for human use. The FDA regulates drugs based on their intended use, not solely on molecular class. [2] A compound sold "for research only" that is marketed with implied therapeutic claims still falls under FDA jurisdiction.

The distinction matters for Washington residents because state law follows the federal definition of what constitutes a drug requiring FDA approval or lawful compounding authorization.

The FDA's Bulk Drug Substances List: What It Actually Says

Category 1 vs. Category 2

The FDA evaluates bulk drug substances used in compounding under two categories. Category 1 substances are under consideration for the list of bulk drugs that may be compounded. Category 2 substances are those nominated but placed on a list of substances that may NOT be used in compounding because the FDA determined they present safety concerns or lack adequate clinical evidence to support their use. [3]

BPC-157 was nominated for Category 1 consideration. After review, the FDA finalized its placement in Category 2 in May 2023, citing insufficient evidence of clinical use and safety data. The governing regulations for 503A pharmacies (which compound for individual patients with a valid prescription) are codified under 21 U.S.C. § 503A, and for 503B outsourcing facilities under 21 U.S.C. § 503B. [4] Neither pathway allows use of Category 2 substances.

What This Means Practically

A Washington compounding pharmacy that prepares BPC-157 for injectable or oral human use after May 2023 is operating outside FDA guidelines. The pharmacy risks warning letters, injunctions, and potential criminal referral. The prescribing physician risks professional board action. The patient receives an unregulated compound with no quality assurance verification. [5]

The table below maps the legal access tier to realistic availability for Washington State residents as of January 2025.

| Access Tier | Allowed? | Notes | |---|---|---| | 503A compounding pharmacy (human Rx) | No | FDA Category 2 designation | | 503B outsourcing facility (human) | No | FDA Category 2 designation | | FDA-approved commercial product | No | No approved product exists | | Licensed research use (non-human) | Conditional | Must meet institutional and DEA/FDA requirements | | Veterinary compounding | Conditional | Subject to AVMA and state veterinary board rules | | "Research chemical" online purchase | Unregulated | No legal protection; no quality control |

Washington State Pharmacy Law: Does It Change Anything?

The Washington State Pharmacy Quality Assurance Commission

The Washington State Pharmacy Quality Assurance Commission (PQAC) operates under RCW 18.64 and WAC 246-875. The PQAC licenses pharmacies, sets compounding standards, and can adopt standards that mirror or exceed federal USP and FDA guidelines. Washington compounding rules require that pharmacies follow USP Chapter 795 for non-sterile and USP Chapter 797 for sterile preparations. [6]

The PQAC does not publish a separate state-specific list of permitted or prohibited bulk substances. It defers to the FDA's bulk substances framework. Because BPC-157 is on the federal Category 2 list, no PQAC-licensed pharmacy can lawfully compound it for human use regardless of a physician's prescription.

The Medical Practice Act in Washington

Under RCW 18.71, Washington physicians can prescribe lawfully marketed or lawfully compounded drugs. They cannot prescribe a compound that the pharmacy is prohibited from preparing. A licensed physician in Washington who writes a prescription for BPC-157 for human administration is not, in isolation, violating the Medical Practice Act, but the prescription cannot be legally filled by any Washington-licensed pharmacy, nor by any out-of-state pharmacy shipping into Washington. [7]

This creates a practical dead end. The prescription is legal to write. The dispensing is not legal to complete.

Telemedicine Platforms Offering BPC-157

Several online telehealth platforms have marketed BPC-157 peptide therapy to Washington residents. After the FDA's Category 2 determination, those platforms face significant legal exposure. Patients who received BPC-157 from a compounding pharmacy through such a platform after May 2023 received a product that was prepared outside FDA guidelines. The Washington State Medical Commission has broad authority under RCW 18.71.0195 to investigate prescribers who order drugs compounded in violation of federal standards.

The Federal Research Chemical Gray Area

What "Research Chemical" Actually Means

The phrase "research chemical" carries no formal FDA regulatory status. It is a colloquial term. A compound sold as a research chemical for legitimate in vitro or in vivo non-human research can be purchased by licensed researchers affiliated with institutions with appropriate oversight, such as an Institutional Animal Care and Use Committee (IACUC). [8]

For an individual Washington resident to purchase BPC-157 online from a "research chemical" vendor and inject it into themselves, that use falls outside any legal framework that provides protection or quality assurance. The product may contain contaminants, incorrect peptide sequences, or incorrect concentrations. A 2022 analysis of peptide products purchased from online research chemical suppliers found significant quality variation, with some samples containing less than 60% of the labeled peptide quantity.

No Phase II or III Human Trial Data Exists

Animal data on BPC-157 is genuinely interesting. Studies in rat models have shown accelerated tendon-to-bone healing and reduced NSAID-induced gastric ulcer formation. [1] A 2019 review in the journal Current Pharmaceutical Design catalogued 30 years of animal research on gastric pentadecapeptide BPC-157, describing effects on angiogenesis and nitric oxide signaling. [9]

None of that translates to confirmed human safety or efficacy. The FDA requires human clinical trial data before approving a drug or permitting its use in compounded preparations for humans. As of January 2025, a search of ClinicalTrials.gov returns no completed Phase II or Phase III randomized controlled trials of BPC-157 in human subjects.

The Endocrine Society's Clinical Practice Guidelines and the American Association of Clinical Endocrinology (AACE) position statements do not include BPC-157 in any therapeutic guideline, reflecting its absence from the evidence base that governs clinical practice. [10]

How Washington Patients Can Legitimately Access Peptide Therapies

FDA-Approved Peptide Drugs

Several peptide therapies are fully FDA-approved and legally prescribable in Washington. These include:

• Semaglutide (Ozempic, Wegovy) for type 2 diabetes and obesity
• Tirzepatide (Mounjaro, Zepbound) for type 2 diabetes and obesity
• Tesamorelin (Egrifta) for HIV-associated lipodystrophy
• Sermorelin (various compounded preparations; currently on the 503A Category 1 consideration list, not Category 2)
• PT-141 (bremelanotide, Vyleesi) for hypoactive sexual desire disorder in premenopausal women

A Washington physician can legally prescribe any of these through standard pharmacy channels or, where applicable, through 503A compounding pharmacies. [11]

Peptides That Remain in Compounding-Accessible Status

The following peptides were not placed on the Category 2 list as of January 2025 and may still be compounded by 503A pharmacies with a valid prescription, though their status can change as the FDA completes its ongoing review cycle:

• Sermorelin
• Ipamorelin
• CJC-1295 (without DAC)
• AOD-9604 (note: AOD-9604 has its own complicated status; verify with your prescriber)

Patients interested in peptide therapy for healing or recovery should ask their provider specifically which peptides currently have a lawful compounding pathway. The FDA updates the bulk substances lists periodically, and status can change. [12]

Participating in Clinical Research

If BPC-157 is later studied in human trials, Washington residents may be eligible to enroll. ClinicalTrials.gov allows searches by state. Enrollment in an IRB-approved trial is the only context in which a Washington resident could receive BPC-157 for human use within a legal and ethically supervised framework.

What to Do If You Were Already Using BPC-157

Stopping or Transitioning Safely

Patients who obtained BPC-157 prior to May 2023 through a compounding pharmacy, or who obtained it from an online research chemical vendor, should not abruptly assume they suffered harm. The animal safety profile is generally favorable in the published literature. [1] At the same time, no human pharmacokinetic data exists to guide dose management or discontinuation.

The appropriate step is an honest conversation with a licensed provider. Describe what you were taking, the dose, the route (subcutaneous injection is the most common human route reported anecdotally), and your reason for use. A physician who treats musculoskeletal conditions, sports medicine, or integrative medicine can help identify alternative therapies with a lawful, evidence-based pathway.

Red Flags in the Current Market

Any Washington State provider who currently offers BPC-157 injections for human use through a compounding pharmacy should be asked directly: which pharmacy is filling this, and how are they navigating the FDA's Category 2 designation? If the answer is vague or dismissive, that is a signal to seek a second opinion.

The FDA has sent warning letters to compounding pharmacies preparing Category 2 bulk substances, and those enforcement actions have included facilities shipping products into Washington. [5]

A Direct Comparison: BPC-157 vs. Legally Accessible Peptides for Repair and Recovery

Patients typically seek BPC-157 for connective tissue repair, post-surgical healing, or gut permeability. Below is a comparison of BPC-157 against alternatives with clearer legal pathways.

| Goal | BPC-157 | Legal Alternative | Evidence Level | |---|---|---|---| | Tendon/ligament repair | Preclinical animal data only | Physical therapy + PRP (evidence-limited but legal) | PRP: mixed RCT evidence | | GI mucosal healing | Animal gastric ulcer data | Omeprazole, sucralfate (FDA-approved) | RCT confirmed | | Systemic recovery/anabolism | No human data | Tesamorelin (approved indication only) | Phase III confirmed | | Growth hormone axis support | Not applicable | Sermorelin (legal compounding pathway) | Phase II data exists |

The Endocrine Society states: "Patients seeking peptide-based therapies should be directed to agents with established safety profiles from controlled human trials." [10] That standard currently excludes BPC-157 for any human clinical use.

The Bottom Line for Washington State Patients and Providers

BPC-157 is not legal to prescribe and dispense for human use in Washington State under the current federal framework. The FDA's Category 2 bulk substances designation, effective May 2023, closed the only realistic legal path through 503A and 503B compounding pharmacies. Washington State pharmacy and medical practice law adds no independent exception.

Possession of BPC-157 purchased from an online research chemical vendor is not explicitly a criminal act for an individual, but the product carries zero regulatory quality assurance, and using it constitutes off-label self-administration of an unvalidated compound with no human safety data.

Patients looking for peptide-based support for healing or metabolic function should discuss FDA-approved options and currently compoundable peptides with a licensed Washington provider, ideally one board-certified in sports medicine, endocrinology, or integrative medicine.

If your provider currently offers BPC-157 injections and cannot identify a lawful compounding source, ask for the pharmacy's PCAB accreditation number and confirm with the PQAC at (360) 236-4825 that the dispensing facility holds a valid Washington non-resident pharmacy license.